ALT
Price
$7.57
Change
-$0.00 (-0.00%)
Updated
Sep 17 closing price
48 days until earnings call
KRYS
Price
$189.26
Change
-$0.00 (-0.00%)
Updated
Sep 17 closing price
47 days until earnings call
Ad is loading...

ALT vs KRYS

Header iconALT vs KRYS Comparison
Open Charts ALT vs KRYSBanner chart's image
Altimmune
Price$7.57
Change-$0.00 (-0.00%)
Volume$2.61M
CapitalizationN/A
Krystal Biotech
Price$189.26
Change-$0.00 (-0.00%)
Volume$663.23K
CapitalizationN/A
View a ticker or compare two or three
ALT vs KRYS Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ALT vs. KRYS commentary
Sep 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and KRYS is a StrongSell.

COMPARISON
Comparison
Sep 19, 2024
Stock price -- (ALT: $7.57 vs. KRYS: $189.26)
Brand notoriety: ALT and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 107% vs. KRYS: 247%
Market capitalization -- ALT: $538.01M vs. KRYS: $5.44B
ALT [@Biotechnology] is valued at $538.01M. KRYS’s [@Biotechnology] market capitalization is $5.44B. The market cap for tickers in the [@Biotechnology] industry ranges from $609.91B to $0. The average market capitalization across the [@Biotechnology] industry is $3.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 1 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while KRYS’s TA Score has 4 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 5 bearish.
  • KRYS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ALT and KRYS are a good buy in the short-term.

Price Growth

ALT (@Biotechnology) experienced а +8.76% price change this week, while KRYS (@Biotechnology) price change was +2.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.17%. For the same industry, the average monthly price growth was +1.67%, and the average quarterly price growth was -2.02%.

Reported Earning Dates

ALT is expected to report earnings on Nov 05, 2024.

KRYS is expected to report earnings on Nov 04, 2024.

Industries' Descriptions

@Biotechnology (+1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($5.44B) has a higher market cap than ALT($538M). KRYS YTD gains are higher at: 52.555 vs. ALT (-32.711). KRYS has higher annual earnings (EBITDA): 120M vs. ALT (-100.91M). KRYS has more cash in the bank: 560M vs. ALT (165M). ALT has less debt than KRYS: ALT (1.86M) vs KRYS (7.69M). KRYS has higher revenues than ALT: KRYS (166M) vs ALT (409K).
ALTKRYSALT / KRYS
Capitalization538M5.44B10%
EBITDA-100.91M120M-84%
Gain YTD-32.71152.555-62%
P/E RatioN/A47.91-
Revenue409K166M0%
Total Cash165M560M29%
Total Debt1.86M7.69M24%
FUNDAMENTALS RATINGS
ALT vs KRYS: Fundamental Ratings
ALT
KRYS
OUTLOOK RATING
1..100
6557
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
795
SMR RATING
1..100
9859
PRICE GROWTH RATING
1..100
3743
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (79) in the Pharmaceuticals Major industry is in the same range as ALT (84) in the Miscellaneous Commercial Services industry. This means that KRYS’s stock grew similarly to ALT’s over the last 12 months.

KRYS's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for ALT (79) in the Miscellaneous Commercial Services industry. This means that KRYS’s stock grew significantly faster than ALT’s over the last 12 months.

KRYS's SMR Rating (59) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALT (98) in the Miscellaneous Commercial Services industry. This means that KRYS’s stock grew somewhat faster than ALT’s over the last 12 months.

ALT's Price Growth Rating (37) in the Miscellaneous Commercial Services industry is in the same range as KRYS (43) in the Pharmaceuticals Major industry. This means that ALT’s stock grew similarly to KRYS’s over the last 12 months.

ALT's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as KRYS (100) in the Pharmaceuticals Major industry. This means that ALT’s stock grew similarly to KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTKRYS
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 8 days ago
84%
Bullish Trend 29 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
N/A
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTXNX42.560.19
+0.45%
FullerThaler Behavioral Sm-Cp Gr Inv
TLAFX13.130.02
+0.15%
Transamerica Large Core ESG R4
JRSIX11.79N/A
N/A
JH Adaptive Risk Mgd U.S. Eq I
GRGVX21.52N/A
N/A
Goldman Sachs U.S. Equity ESG R
DFGEX11.61-0.08
-0.68%
DFA Global Real Estate Securities Port

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with BEAM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-2.58%
BEAM - KRYS
49%
Loosely correlated
-0.16%
ORMP - KRYS
48%
Loosely correlated
+1.21%
CLDX - KRYS
47%
Loosely correlated
-3.78%
RXRX - KRYS
46%
Loosely correlated
+1.65%
NTLA - KRYS
46%
Loosely correlated
+4.83%
More